Sciensus

Last updated
Sciensus
Founded1992
FounderCharles Walsh
Headquarters
Burton on Trent
,
England
Number of employees
1,600

Sciensus (formerly Healthcare at Home) is a global life sciences business established in 1992 by founder and former chairman Charles Walsh based in Burton on Trent.

The company supplies a wide range of specialist medications and patient support programmes for chronic, cancer and rare disease patients, with around 1,600 employees dealing with more than 230,000 patients a year. [1] It works with every NHS trust in the UK. [2]

In Spring 2015, Healthcare at Home reverted to using in house logistics rather than working with a third party for all deliveries.

In Autumn 2015, the company went through a full corporate rebranding, including new logos, literature, strap line and website in an attempt to re-establish the company's status in the market. [3]

The company's name was changed in 2022 from "Healthcare at Home LTD" to "Sciensus Pharma Limited", using only "Sciensus" to refer to themselves from then on. [4]

In July 2023, 1 patient died and 3 were hospitalised after being administered unlicensed versions of cabazitaxel chemotherapy provided by Sciensus. [5] This follows reports in May 2023 of complaints of poor service and delays raised about the company, sparking a possible CQC review. [6] [7] [8] This resulted in "partial suspension" of its licence by the Medicines and Healthcare products Regulatory Agency (MHRA). [9]

History

In 2013 Healthcare at Home took over almost 3,000 patients from another drug delivery company, Medco Health Solutions which pulled out of the UK market. Subsequently, the company struggled to maintain services. In March 2014 Healthcare at Home said that it was no longer accepting new ‘high risk’ patients such as those suffering from haemophilia or respiratory diseases like cystic fibrosis because it could not guarantee getting their drugs to them on time or in full. The company blamed IT issues and a ‘system failure’ relating to the firm's outsourcing of its logistics and warehousing departments. Dave Roberts, chief executive of the National Clinical Homecare Association, says there are questions about whether the rapid growth and low profit margins in the sector have contributed to the situation. ‘There’s been 20% growth in this sector year on year for several years now in terms of numbers of patients – that’s a very rapid expansion. But profits in this sector are just 2-4%. That is a poor return given the extent of capital investment needed and the governance and logistics issues. As NHS budgets have fallen, all the slack has been cut out of contracts,’ Roberts added.

In its 2014 accounts Healthcare at Home, which is majority-owned by private equity firm Vitruvian Partners, reported a turnover of £1bn, with pretax profits of just £15m. [10]

The chief executive Mike Gordon stepped down in June 2014 after the revelation that seven per cent of the firm's 150,000 patients had not received their medication on time or in full during the last six months. [11]

In May 2021 it was reported that the firm had missed almost 10,000 medicine deliveries when it introduced a new IT system in October 2020 and it was put in special measures by the Care Quality Commission. The inspectors found they failed to properly investigate some health and safety incidents and "did not always learn lessons when things went wrong". [12]

On 16 October 2023, Sciencus were given 28 days to reform the firm's complaints handling process due to issues around ignoring patients concerns. The CEO of Sciencus received a written warning from the Rob Behrens, Parliamentary and Health Service Ombudsman. [13]

Related Research Articles

<span class="mw-page-title-main">Healthcare industry</span> Economic sector focused on health

The healthcare industry is an aggregation and integration of sectors within the economic system that provides goods and services to treat patients with curative, preventive, rehabilitative, and palliative care. It encompasses the creation and commercialization of products and services conducive to the preservation and restoration of well-being. The contemporary healthcare sector comprises three fundamental facets, namely services, products, and finance. It can be further subdivided into numerous sectors and categories and relies on interdisciplinary teams of highly skilled professionals and paraprofessionals to address the healthcare requirements of both individuals and communities.

<span class="mw-page-title-main">National Institute for Health and Care Excellence</span> Non-departmental public body of the Department of Health in the UK

The National Institute for Health and Care Excellence (NICE) is an executive non-departmental public body, in England, of the Department of Health and Social Care, that publishes guidelines in four areas:

<span class="mw-page-title-main">Apollo Hospitals</span> Indian hospital chain

Apollo Hospitals Enterprise Limited is an Indian multinational healthcare group headquartered in Chennai. It is the largest for-profit private hospital network in India, with a network of 71 owned and managed hospitals. Along with the eponymous hospital chain, the company also operates pharmacies, primary care and diagnostic centres, telehealth clinics, and digital healthcare services among others through its subsidiaries.

The pharmaceutical industry is one of the leading industries in the People's Republic of China, covering synthetic chemicals and drugs, prepared Chinese medicines, medical devices, apparatus and instruments, hygiene materials, packing materials, and pharmaceutical machinery. China has the second-largest pharmaceutical market in the world as of 2017 which is worth US$110 billion. China accounts for 20% of the world's population but only a small fraction of the global drug market. China's changing health-care environment is designed to extend basic health insurance to a larger portion of the population and give individuals greater access to products and services. Following the period of change, the pharmaceutical industry is expected to continue its expansion.

Mitie Group PLC is a British strategic outsourcing and energy services company. It provides infrastructure consultancy, facilities management, property management, energy and healthcare services. It has a head office at The Shard in London and more than 200 smaller offices throughout the United Kingdom and Ireland. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.

<span class="mw-page-title-main">Weston General Hospital</span> NHS district hospital

Weston General Hospital is an NHS district general hospital in the town of Weston-super-Mare, Somerset, England, operated by University Hospitals Bristol and Weston NHS Foundation Trust. As of June 2019, the hospital had 261 beds and around 1,800 clinical and non-clinical staff. It has a part-time Accident & Emergency department, an intensive care unit, an oncology and haematology day unit, and a day case unit. The hospital also has a 12-bed private unit, The Waterside Suite, wholly owned by the hospital trust, with profits being re-invested into the main hospital.

<span class="mw-page-title-main">NHS Scotland</span> Publicly-funded healthcare system in Scotland

NHS Scotland, sometimes styled NHSScotland, is the publicly–funded healthcare system in Scotland and one of the four systems that make up the National Health Service in the United Kingdom. It operates 14 territorial NHS boards across Scotland, supported by seven special non-geographic health boards, and Public Health Scotland.

The Clinical Practice Research Datalink (CPRD) is an observational and interventional research service that operates as part of the UK Department of Health. It is jointly funded by the National Institute for Health and Care Research(NIHR) and the Medicines and Healthcare products Regulatory Agency (MHRA). CPRD is working closely with the extensive primary care, topic specific and comprehensive NIHR research networks and with NHS Digital.

<span class="mw-page-title-main">Healthcare in the United Kingdom</span>

Healthcare in the United Kingdom is a devolved matter, with England, Northern Ireland, Scotland and Wales each having their own systems of publicly funded healthcare, funded by and accountable to separate governments and parliaments, together with smaller private sector and voluntary provision. As a result of each country having different policies and priorities, a variety of differences have developed between these systems since devolution.

<span class="mw-page-title-main">Criticism of the National Health Service (England)</span>

Criticism of the National Health Service (England) includes issues such as access, waiting lists, healthcare coverage, and various scandals. The National Health Service (NHS) is the publicly funded health care system of England, created under the National Health Service Act 1946 by the post-war Labour government of Clement Attlee. It has come under much criticism, especially during the early 2000s, due to outbreaks of antibiotic resistant infections such as MRSA and Clostridium difficile infection, waiting lists, and medical scandals such as the Alder Hey organs scandal. However, the involvement of the NHS in scandals extends back many years, including over the provision of mental health care in the 1970s and 1980s (ultimately part of the reason for the Mental Health Act 1983), and overspends on hospital newbuilds, including Guy's Hospital Phase III in London in 1985, the cost of which shot up from £29 million to £152 million.

The Care Quality Commission (CQC) is an executive non-departmental public body of the Department of Health and Social Care of the United Kingdom. It was established in 2009 to regulate and inspect health and social care providers in England.

Healthcare in England is mainly provided by the National Health Service (NHS), a public body that provides healthcare to all permanent residents in England, that is free at the point of use. The body is one of four forming the UK National Health Service as health is a devolved matter; there are differences with the provisions for healthcare elsewhere in the United Kingdom, and in England it is overseen by NHS England. Though the public system dominates healthcare provision in England, private health care and a wide variety of alternative and complementary treatments are available for those willing and able to pay.

<span class="mw-page-title-main">Spire Healthcare</span> British private healthcare company

Spire Healthcare Group plc is the second-largest provider of private healthcare in the United Kingdom. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.

Circle Health Group is a private healthcare provider in the United Kingdom, and is the country's biggest private hospital provider. The company was founded in 2004 and rebranded as Circle Health Group in 2019 after acquiring a rival, BMI Healthcare; in the same year it began an expansion in China. In 2023 the company was acquired by an Abu Dhabi-based holding company called PureHealth.

The Cancer Drugs Fund (CDF) was introduced in England in 2011. It was established in order to provide a means by which National Health Service (NHS) patients in England could get cancer drugs rejected by National Institute for Health and Care Excellence because they were not cost effective. Its establishment was confirmed by the UK government's coalition agreement in 2010, and by the White Paper, Equity and excellence – Liberating the NHS.

<span class="mw-page-title-main">Clatterbridge Cancer Centre NHS Foundation Trust</span> UK public sector healthcare provider

The Clatterbridge Cancer Centre is an NHS Foundation Trust, which specialises in the treatment of cancer. The centre is one of several specialist hospitals located within Merseyside; alongside Liverpool Heart and Chest Hospital, Alder Hey Children's Hospital, Liverpool Women's Hospital, and the Walton Centre.

The Royal Cornwall Hospitals NHS Trust is an NHS trust which runs West Cornwall Hospital, St Michael's Hospital, Royal Cornwall Hospital, and St Austell Hospital - Penrice Birthing Unit, in Cornwall, England.

<span class="mw-page-title-main">Advanz Pharma</span> British pharmaceutical company

Advanz Pharma Corp. is a British multinational pharmaceutical company headquartered in London. It changed its name from Concordia Healthcare Corp. in November 2018. The company focuses on a number of therapy areas including endocrinology, ophthalmology, urology, anti-infectives, pain management, central nervous system disorders, oncology, haematology, cardiology and intensive care medicine. The company also focuses on acquiring legacy pharmaceutical compounds which are usually off-patent. The operational headquarters is in London, UK, operations centre in Mumbai, India and regional hubs in Europe, Australia and Canada.

<span class="mw-page-title-main">Private healthcare in the United Kingdom</span>

Private healthcare in the UK, where universal state-funded healthcare is provided by the National Health Service, is a niche market.

<span class="mw-page-title-main">Cera Care</span> UK home care company

Cera Care is a digital-first healthcare-at-home company delivering care, nursing, telehealth and repeat prescription services in people’s homes via technology. Founded in 2015, the company provides elderly and vulnerable communities with care in their own homes, and allows families to arrange the care.

References

  1. ↑ "Sciensus Pharma Services Limited (formerly Healthcare at Home Ltd) Annual report and financial statements for the year ended 31 March 2022". UK Government Companies House. 2022-03-31. Archived from the original on 2023-02-01. Retrieved 2023-02-01.
  2. ↑ "Supplier to 'every NHS trust' placed in special measures". Health Service Journal. 13 May 2021. Retrieved 4 July 2021.
  3. ↑ "Healthcare at Home corporate rebranding".
  4. ↑ "Change company name resolution from Healthcare at Home LTD to Sciensus Pharma Services Limited". UK Government Companies House. 2022-04-12. Archived from the original on 2023-02-01. Retrieved 2023-02-01.
  5. ↑ Gregory, Andrew (7 July 2023). "Patient dies and three hospitalised in Sciensus chemotherapy incident". The Guardian.
  6. ↑ Gregory, Andrew (21 April 2023). "Regulator to review safety concerns over medicines courier used by NHS". The Guardian.
  7. ↑ Burns, Corrinne (2 May 2023). "CQC says it is reviewing concerns about major homecare medicines provider". The Pharmaceutical Journal.
  8. ↑ "Sciensus: Cancer survivor, 16, went weeks without drugs amid delays by NHS-contracted firm". 18 May 2023. Retrieved 7 July 2023.
  9. ↑ "Sciensus: NHS-contracted company has license suspended after death of cancer patient". 24 July 2023. Retrieved 25 July 2023.
  10. ↑ "'Appalling service' provided by Healthcare at Home leaves patients without drugs". Bureau of Investigative Journalism. 2 June 2014. Retrieved 9 June 2014.
  11. ↑ "Healthcare at Home chief Mike Gordon steps down following Bureau revelations". Bureau of Investigative Journalism. 6 June 2014. Retrieved 9 June 2014.
  12. ↑ "Healthcare at Home missed nearly 10,000 medicine deliveries". BBC. 15 May 2021. Retrieved 17 May 2021.
  13. ↑ Gregory, Andrew (2023-10-19). "NHS ombudsman warns Sciensus that patients 'should not be ignored'". The Guardian. ISSN   0261-3077 . Retrieved 2023-10-19.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.